Health Care · Drug Manufacturers - General

Nasus Pharma Ltd. NSRX

$3.17+0.14 (+4.62%)delayed quote · as of 2026-08-03 16:18 UTC

Open NSRX in the workspaceCharts, statements, and the evidence behind every figure — free to start.

Market cap

$37.1M

Previous close

$3.03

Volume

52-week range

$1.98 – $9.99

Verdictconfidence 38% · low

Not enough filed data to publish a verdict for NSRX. The quote above is real; the verdict engine refuses to score on thin inputs rather than guess.

Key ratioslatest filing FY 2025

Value

P/E TTM

—

P/E FWD

—

EV/EBITDA TTM

—

PEG

—

FCF yield FY2025

-13.3%

Growth

Revenue 3y

—

Revenue YoY

—

Expected EPS

—

Quality

Piotroski F

4 / 9

ROIC

—

Gross margin

—

Health

Altman Z

—

Current ratio

2.24

Debt/equity

—

Momentum

vs 50-day

—

vs 200-day

—

52-wk range

15%

FY 2025: revenue $1.2B · net income -$5.9M · free cash flow -$4.9M (SEC EDGAR filings)

ALAN GLOBAL INTELLIGENCE · alanglobalintelligence.comquote as of 2026-08-03 16:18 UTC · fundamentals FY 2025 · SEC EDGAR

Verdict

Reading NSRX’s filed statements…

Continue with NSRX in ALAN

Full evidence trail, financial statements back a decade, valuation history, charts, and alerts.

Open in the workspace Create free account

For information and research only. Not investment advice. ALAN does not place trades or execute orders. Figures come from the sources shown and can lag the market; verify independently before making decisions. Past performance is not predictive of future results.